All That Glitters Isn’t Gold
By Osagie K. Obasogie and Troy Duster,
The Hastings Center Report
| 10. 12. 2011
The increasing use of DNA evidence has revolutionized criminal investigations. Over the past several years, DNA forensics—once thought to be a less reliable identifier than other forensic techniques, such as latent fingerprinting—have now become the evidentiary gold standard in criminal prosecutions. At the same time, non-DNA-based forensic techniques that have incarcerated thousands are coming under fire.
The policy implications of this shifting dynamic—what Michael Lynch and colleagues call an “inversion of credibility”[1]—can be most clearly seen in the National Research Council’s 2009 report, Strengthening Forensic Science in the United States: A Path Forward. Conducted at Congress’s request by a highly esteemed committee, this report—over three hundred pages—assesses the current state of forensic science.
The committee found remarkable shortcomings in what they call the forensic science knowledge base, noting that the scientific theories and methods used to substantiate many forensic claims frequently cannot withstand close scrutiny. They found an alarmingly “wide variability in capacity, oversight, staffing,
certification, and accreditation.”[2] For example, lack of transparency, susceptibility to bias, and questionable methodologies for friction ridge analyses (analyses of the prints left by...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...